

the lipopeptide, ester of the lipopeptide, or mixture thereof as an inactivating agent, at room temperature for 30 minutes up to 2 hours, wherein

D1
the agent is added to said products at a concentration of 1-100 μ M and an inactivation factor $> 10^4$ is achieved, wherein the agent directly inactivates any lipid-enveloped viruses present in said product.

D2
10. (Twice Amended) The method according to claim 1 characterized in that one or more viruses selected from the group consisting of herpes viruses, human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency virus (SIV_{agm}), vesicular stomatitis virus (VSV), and Semliki-Forest virus (SFV) are inactivated.

(Please add the following new claims)

ab
D3
18. (New) The method of claim 1, wherein the non-cell culture biological products are selected from the group consisting of blood products, products isolated from blood, and biotechnological pharmaceutical products consisting of human proteins.

19. (New) The method of claim 18, wherein the products isolated from blood are selected from the group consisting of vaccines.